Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039245 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02039245 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 12 participants.
The verdict
NCT02039245, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the multiple dose pharmacokinetics of 2 Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination tablets (150 mg/1,000 mg each) following once-daily oral dosing in healthy participants.
Interventions
- DRUG CANA/MET XR FDC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02039245
The ClinicalTrials.gov registry entry for NCT02039245 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CANA/MET XR FDC is the first listed.
NCT02039245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02039245 about?
NCT02039245 is a clinical study titled "Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination". The purpose of this study is to evaluate the multiple dose pharmacokinetics of 2 Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination tablets (150 mg/1,000 mg each) following once-daily oral dosing in healthy participants.
What is the current status of trial NCT02039245?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-01. Estimated completion is 2014-03.
What interventions are being tested in trial NCT02039245?
The interventions under investigation include: CANA/MET XR FDC (DRUG).
Who is sponsoring clinical trial NCT02039245?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.